Evidence & Safety Guide • Seizure-Focused Authority Page
CBD for Seizures: What the Evidence Shows, What It Does Not, and What to Ask Your Neurologist
Prescription cannabidiol has FDA-reviewed evidence for specific seizure disorders. Retail CBD oils, including Full-Spectrum products, are a different product category and are not FDA-approved seizure treatments. This guide explains the clinical evidence, dose and formulation differences, the Entourage Effect hypothesis, medication-safety issues, emergency seizure guidance, and what to bring to a neurologist or pharmacist.
Clinical trial evidence
Full-Spectrum context
Medication safety
Neurologist-first guidance
Written by: Bill Polyniak, Founder of Bluegrass Hemp Oil and Kentucky Cannabis Company, for hemp cultivation, extraction, Full-Spectrum formulation, manufacturing, product labels, laboratory testing, Certificates of Analysis, and product-quality context.
Clinical review status: this authority revision is prepared for independent pharmacist review of prescription-cannabidiol pharmacology, antiseizure-medication interactions, liver safety, dose interpretation, therapeutic drug monitoring, and medication-safety statements before a clinical reviewer is publicly credited.
Quick answer
Is CBD Approved for Seizures?
One cannabidiol medication is FDA approved for specific seizure disorders. EPIDIOLEX is a prescription cannabidiol oral solution indicated for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients 1 year of age and older.
That approval does not apply to retail CBD oils, gummies, capsules, Full-Spectrum products, or Genesis Blend. Retail CBD products should not be presented as seizure treatments.
Prescription evidence
EPIDIOLEX was studied in randomized, double-blind, placebo-controlled trials for defined seizure disorders.
Retail CBD
Retail products differ in formulation, concentration, THC content, labeling, and evidence. They are not FDA-approved seizure medications.
Best next step
If seizures are part of your health history, bring the exact product label, intended dose, COA, and medication list to your neurologist or pharmacist.
Prescription cannabidiol
What FDA Approval Actually Means
FDA approval does not mean that “CBD in general” is approved for seizures. It means a specific prescription cannabidiol formulation was evaluated for specific indications, using defined dosing, manufacturing controls, clinical trials, adverse-event monitoring, and prescribing instructions.
| Condition | What current labeling says | Typical labeled dose context |
|---|---|---|
| Lennox-Gastaut syndrome | EPIDIOLEX is indicated for seizures associated with LGS in patients age 1 year and older. | Starts at 5 mg/kg/day, typically increases to 10 mg/kg/day, and may be increased to 20 mg/kg/day when clinically appropriate. |
| Dravet syndrome | EPIDIOLEX is indicated for seizures associated with DS in patients age 1 year and older. | Starts at 5 mg/kg/day, typically increases to 10 mg/kg/day, and may be increased to 20 mg/kg/day when clinically appropriate. |
| Tuberous sclerosis complex | EPIDIOLEX is indicated for seizures associated with TSC in patients age 1 year and older. | Starts at 5 mg/kg/day and is titrated to a recommended maintenance dosage of 25 mg/kg/day. |
Important: these are prescription-label dose ranges, not instructions for self-treatment and not retail-CBD dosing recommendations. A prescriber determines whether prescription cannabidiol is appropriate and how it should be used.
Primary reference: current EPIDIOLEX prescribing information.
What controlled trials showed
The Evidence Is Condition-Specific, Dose-Specific, and Product-Specific
The strongest evidence for cannabidiol and seizures comes from controlled trials of prescription EPIDIOLEX, not from a generic category of retail CBD products.
Drop seizures
In one trial, median drop-seizure frequency fell 44% with 20 mg/kg/day EPIDIOLEX versus 22% with placebo. In another, reductions were 37% with 10 mg/kg/day and 42% with 20 mg/kg/day versus 17% with placebo.
Convulsive seizures
Median convulsive-seizure frequency fell 39% with 20 mg/kg/day EPIDIOLEX versus 13% with placebo in the pivotal study.
TSC-associated seizures
Median TSC-associated seizure frequency fell 43% with 25 mg/kg/day EPIDIOLEX versus 20% with placebo in the pivotal trial.
What these results prove: prescription cannabidiol reduced seizure frequency more than placebo in these studied conditions under controlled medical protocols.
What they do not prove: that every CBD product, every Full-Spectrum extract, or every dose has the same effect.
Dose is part of the evidence
Why Prescription-CBD Doses and Retail-CBD Doses Should Not Be Blurred Together
Prescription cannabidiol studies frequently use weight-based dosing. For a 70 kg (154 lb) adult, 10 mg/kg/day equals about 700 mg of CBD per day, while 20 mg/kg/day equals about 1,400 mg per day. TSC maintenance dosing at 25 mg/kg/day would equal about 1,750 mg per day for that body weight.
Those examples show why the word “CBD” by itself is not enough to compare two products or two studies. Total CBD exposure can differ dramatically.
Approximately 10 mg CBD per mL
Approximately 25 mg CBD per mL
Approximately 20–100 mg total CBD per day, depending on the individual
Often use weight-based dosing that can equal hundreds or more than one thousand milligrams per day
This is not a claim that lower-dose Full-Spectrum CBD treats seizures or is safer for epilepsy. It is a dose-comparison point. Clinical results and adverse-event findings from very high prescription-CBD exposure should not be casually converted into identical expectations for substantially lower retail doses, and lower dose does not mean zero interaction risk.
Different formulations, different evidence
Purified Prescription CBD and Full-Spectrum CBD Are Not Interchangeable
Prescription cannabidiol
EPIDIOLEX is a standardized 100 mg/mL purified cannabidiol oral solution with FDA-reviewed clinical evidence, labeling, manufacturing controls, interaction warnings, and required liver monitoring.
Retail Full-Spectrum CBD
A Full-Spectrum hemp extract contains CBD within a broader plant profile that may include minor cannabinoids, cannabinoid acids, terpenes, flavonoids, and trace THC. Product composition and dose can vary by manufacturer.
Those differences matter scientifically, but they do not justify calling retail Full-Spectrum CBD an approved seizure treatment. Prescription evidence should inform safety discussions without being presented as direct proof that a retail formulation will perform the same way.
For the detailed comparison of prescription CBD, Full-Spectrum CBD, liver safety, dose, and formulation, see Epidiolex vs. Full-Spectrum CBD.
Full-Spectrum research
What Does the “Entourage Effect” Evidence Actually Suggest?
The Entourage Effect is the hypothesis that cannabinoids, terpenes, and other plant constituents can influence one another's pharmacology through additive, synergistic, antagonistic, absorption, or metabolic effects. It is a plausible research question, not proof that every Full-Spectrum product is clinically superior.
2018 observational epilepsy analysis
A meta-analysis of observational treatment-resistant epilepsy studies reported an average CBD dose of 6.0 mg/kg/day for CBD-rich extracts versus 25.3 mg/kg/day for purified CBD.
At the conventional threshold of at least 50% seizure reduction, responder rates did not differ significantly between the groups.
Why that finding is interesting
The CBD-rich extract group used substantially less CBD on average and reported fewer adverse effects. The authors proposed synergistic phytochemical effects as one possible explanation, but they explicitly noted that controlled trials are needed to confirm that explanation.
The strongest conclusion: observational data are consistent with the possibility that broader extracts may behave differently from purified CBD and may sometimes be used at lower CBD exposure. They do not prove that the Entourage Effect causes the difference, and they do not establish that retail Genesis Blend treats seizures.
Research: Pamplona et al. (2018), observational meta-analysis of CBD-rich extracts versus purified CBD.
Medication safety
CBD, Clobazam, Valproate, Sedation, and Other Antiseizure Medications
People with epilepsy often take more than one antiseizure medication. CBD can change the exposure or safety profile of certain drugs, which is why a seizure-focused CBD discussion should include the medication list, not just the CBD bottle.
| Medication / issue | What the evidence shows | Why it matters |
|---|---|---|
| Clobazam | CBD can substantially increase exposure to N-desmethylclobazam, clobazam's active metabolite. | Clobazam-related adverse effects and sedation can increase. |
| Valproate | Valproate is associated with a higher incidence of liver-enzyme elevations when used with prescription cannabidiol. | The important concern is liver safety rather than simply a large rise in valproate blood concentration. |
| Other antiseizure medications | Expanded-access data found changes in serum concentrations of several antiseizure drugs as CBD doses increased. | Medication-specific drug-level monitoring can be useful in selected clinical situations. |
| Sedation | CBD can cause somnolence, and concomitant CNS depressants can add to sedation risk. | Driving, falls, alertness, alcohol use, and other sedating medications may need review. |
For the deeper pharmacology and medication-specific evidence, see CBD Interactions: Medications, Liver Safety, and Blood Monitoring.
Research: Gaston et al. (2017) and the current EPIDIOLEX prescribing information.
Bloodwork is not one single test
Liver Tests and Medication Blood Levels Answer Different Questions
Liver-function monitoring
ALT, AST, and bilirubin help identify liver-enzyme abnormalities or possible liver injury. Current EPIDIOLEX labeling requires these tests before treatment, at 1 month, 3 months, and 6 months, and periodically thereafter as clinically indicated.
Therapeutic drug monitoring
This measures the concentration of a particular antiseizure medication or active metabolite in the bloodstream. It can be useful for selected drugs when interactions, toxicity, adherence, pregnancy, breakthrough seizures, dose changes, or organ-function changes make levels clinically informative.
Not every antiseizure medication requires routine blood-level testing, and one monitoring schedule does not apply to every patient. The neurologist or pharmacist should decide which laboratory tests are appropriate for the complete medication regimen.
Make the appointment more useful
What to Bring to Your Neurologist or Pharmacist if You Are Considering CBD
Do not start, stop, reduce, or replace an antiseizure medication because of CBD information online. Abrupt changes in antiseizure therapy can be dangerous and should be directed by the treating clinician.
Retail CBD quality
If a Clinician Is Reviewing a Retail CBD Product, Give Them Useful Product Information
A retail CBD label or Certificate of Analysis cannot prove that a product treats seizures. It can, however, help a clinician understand what the patient is actually taking.
CBD concentration
Look for a clear amount per mL or serving and total CBD per container.
THC content
Full-Spectrum products may contain trace THC. The batch COA should show measured cannabinoid content.
Contaminant testing
Review testing for pesticides, heavy metals, residual solvents, microbes, and other relevant contaminants.
Bluegrass Hemp Oil provides Certificates of Analysis and a CBD lab-testing guide. These resources support product transparency, not seizure-treatment claims.
Common questions
CBD for Seizures FAQ
Is CBD approved for seizures?
EPIDIOLEX, a prescription cannabidiol oral solution, is FDA approved for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients 1 year of age and older. Retail CBD products are not FDA-approved seizure treatments.
Is Full-Spectrum CBD the same as EPIDIOLEX?
No. EPIDIOLEX is a standardized prescription cannabidiol medication. Full-Spectrum hemp extracts contain CBD within a broader plant profile and may contain minor cannabinoids, terpenes, cannabinoid acids, and trace THC.
Can Genesis Blend be used to treat seizures?
Genesis Blend Full-Spectrum CBD Oil is not an FDA-approved seizure treatment and should not be presented as a replacement for prescribed epilepsy therapy. Anyone with seizures should discuss the exact product and intended dose with a neurologist or qualified healthcare professional.
What does the Entourage Effect have to do with seizure research?
The Entourage Effect is a hypothesis that multiple plant constituents may influence one another's pharmacology. Observational epilepsy data found lower average CBD doses with CBD-rich extracts than purified CBD, but controlled trials are needed to determine whether an Entourage Effect explains the difference.
Can CBD interact with seizure medication?
Yes. CBD can interact with certain antiseizure medications. Clobazam and valproate are especially important examples, but the mechanism and clinical importance differ by drug. Medication changes should be directed by the treating clinician.
Should someone taking seizure medications have blood tests?
Sometimes. Liver-function tests and therapeutic drug monitoring are different. The need for either depends on the medication, CBD exposure, liver health, symptoms, and the patient's complete treatment plan.
Can a person stop seizure medication and try CBD instead?
No. Do not stop, reduce, replace, or change antiseizure medication because of CBD information online. Changes in epilepsy treatment should be directed by the clinician responsible for care.
When is a seizure an emergency?
Call 911 if a seizure lasts longer than 5 minutes, another seizure starts soon afterward, the person has trouble breathing or waking, is injured, the seizure occurs in water, or it is the person's first seizure. Pregnancy and loss of consciousness with diabetes are also reasons for emergency help.
What should a CBD Certificate of Analysis show?
A useful COA should show measured CBD and THC content, batch information, and relevant contaminant testing. A COA supports product transparency but does not prove that a retail product treats seizures.
Primary and clinical references
Sources Used for This Guide
- DailyMed: current EPIDIOLEX prescribing information
- Pamplona et al. (2018): CBD-rich extracts versus purified CBD in treatment-resistant epilepsy
- Gaston et al. (2017): Cannabidiol interactions with commonly used antiepileptic drugs
- CDC: First Aid for Seizures
Last evidence review: November 3, 2026. Prescription labeling and clinical evidence can change. Medication-specific decisions should use current prescribing information and the treating clinician's judgment.